Cargando…

1149. Reducing Piperacillin/Tazobactam Use in Children with Acute Perforated Appendicitis

BACKGROUND: Children with perforated appendicitis have more frequent complications compared with nonperforated appendicitis. Existing data suggest broad-spectrum antibiotics are not superior to narrow-spectrum antibiotics for this condition. In an effort to safely decrease broad-spectrum antibiotic...

Descripción completa

Detalles Bibliográficos
Autores principales: Seddik, Talal B, Bio, Laura, Bassett, Hannah, Contopoulos-Ioannidis, Despina, Qureshi, Lubna, Schwenk, Hayden
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6809157/
http://dx.doi.org/10.1093/ofid/ofz360.1013
_version_ 1783461916052553728
author Seddik, Talal B
Bio, Laura
Bassett, Hannah
Contopoulos-Ioannidis, Despina
Qureshi, Lubna
Schwenk, Hayden
author_facet Seddik, Talal B
Bio, Laura
Bassett, Hannah
Contopoulos-Ioannidis, Despina
Qureshi, Lubna
Schwenk, Hayden
author_sort Seddik, Talal B
collection PubMed
description BACKGROUND: Children with perforated appendicitis have more frequent complications compared with nonperforated appendicitis. Existing data suggest broad-spectrum antibiotics are not superior to narrow-spectrum antibiotics for this condition. In an effort to safely decrease broad-spectrum antibiotic use at our hospital, we evaluated the impact of an antimicrobial stewardship program (ASP) intervention on the use of piperacillin/tazobactam (PT) and clinical outcomes in children with perforated appendicitis. METHODS: Single-center, retrospective cohort study of children ≤ 18 years with perforated appendicitis who underwent primary appendectomy. Children with primary nonoperative management or interval appendectomy were excluded. Prior to the intervention, children at our hospital routinely received PT for perforated appendicitis. An electronic health record (EHR)-integrated guideline that recommended ceftriaxone and metronidazole for perforated appendicitis was released on July 1, 2017 (Figure 1). We compared PT utilization, measured in days of therapy (DOT) per 1,000 patient-days, and clinical outcomes before and after the intervention. RESULTS: A total of 74 children with perforated appendicitis were identified: 23 during the pre-intervention period (June 1, 2016 to June 30, 2017) and 51 post-intervention (July 1, 2017 to September 30, 2018). Thirty-three patients (45%) were female and the median age was 8 years (IQR: 5–11.75 years). Post-intervention rate of guideline compliance was 84%. PT use decreased from 556 DOT per 1000 patient-days to 131 DOT per 1000 patient-days; incidence rate ratio of 0.24 (95% CI: 0.16–0.35), post-intervention vs. pre-intervention. There was no statistically significant difference in duration of intravenous antibiotics, total antibiotic duration, postoperative length of stay (LOS), total LOS, ED visits/readmission, or surgical site infection (SSI) between pre- and post-intervention periods (Table 1). CONCLUSION: An EHR-integrated ASP intervention targeting children with perforated appendicitis resulted in decreased broad-spectrum antibiotic use with no statistically significant difference in clinical outcomes. Larger, multicenter trials are needed to confirm our findings. [Image: see text] [Image: see text] DISCLOSURES: All authors: No reported disclosures.
format Online
Article
Text
id pubmed-6809157
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher Oxford University Press
record_format MEDLINE/PubMed
spelling pubmed-68091572019-10-28 1149. Reducing Piperacillin/Tazobactam Use in Children with Acute Perforated Appendicitis Seddik, Talal B Bio, Laura Bassett, Hannah Contopoulos-Ioannidis, Despina Qureshi, Lubna Schwenk, Hayden Open Forum Infect Dis Abstracts BACKGROUND: Children with perforated appendicitis have more frequent complications compared with nonperforated appendicitis. Existing data suggest broad-spectrum antibiotics are not superior to narrow-spectrum antibiotics for this condition. In an effort to safely decrease broad-spectrum antibiotic use at our hospital, we evaluated the impact of an antimicrobial stewardship program (ASP) intervention on the use of piperacillin/tazobactam (PT) and clinical outcomes in children with perforated appendicitis. METHODS: Single-center, retrospective cohort study of children ≤ 18 years with perforated appendicitis who underwent primary appendectomy. Children with primary nonoperative management or interval appendectomy were excluded. Prior to the intervention, children at our hospital routinely received PT for perforated appendicitis. An electronic health record (EHR)-integrated guideline that recommended ceftriaxone and metronidazole for perforated appendicitis was released on July 1, 2017 (Figure 1). We compared PT utilization, measured in days of therapy (DOT) per 1,000 patient-days, and clinical outcomes before and after the intervention. RESULTS: A total of 74 children with perforated appendicitis were identified: 23 during the pre-intervention period (June 1, 2016 to June 30, 2017) and 51 post-intervention (July 1, 2017 to September 30, 2018). Thirty-three patients (45%) were female and the median age was 8 years (IQR: 5–11.75 years). Post-intervention rate of guideline compliance was 84%. PT use decreased from 556 DOT per 1000 patient-days to 131 DOT per 1000 patient-days; incidence rate ratio of 0.24 (95% CI: 0.16–0.35), post-intervention vs. pre-intervention. There was no statistically significant difference in duration of intravenous antibiotics, total antibiotic duration, postoperative length of stay (LOS), total LOS, ED visits/readmission, or surgical site infection (SSI) between pre- and post-intervention periods (Table 1). CONCLUSION: An EHR-integrated ASP intervention targeting children with perforated appendicitis resulted in decreased broad-spectrum antibiotic use with no statistically significant difference in clinical outcomes. Larger, multicenter trials are needed to confirm our findings. [Image: see text] [Image: see text] DISCLOSURES: All authors: No reported disclosures. Oxford University Press 2019-10-23 /pmc/articles/PMC6809157/ http://dx.doi.org/10.1093/ofid/ofz360.1013 Text en © The Author(s) 2019. Published by Oxford University Press on behalf of Infectious Diseases Society of America. http://creativecommons.org/licenses/by-nc-nd/4.0/ This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs licence (http://creativecommons.org/licenses/by-nc-nd/4.0/), which permits non-commercial reproduction and distribution of the work, in any medium, provided the original work is not altered or transformed in any way, and that the work is properly cited. For commercial re-use, please contact journals.permissions@oup.com
spellingShingle Abstracts
Seddik, Talal B
Bio, Laura
Bassett, Hannah
Contopoulos-Ioannidis, Despina
Qureshi, Lubna
Schwenk, Hayden
1149. Reducing Piperacillin/Tazobactam Use in Children with Acute Perforated Appendicitis
title 1149. Reducing Piperacillin/Tazobactam Use in Children with Acute Perforated Appendicitis
title_full 1149. Reducing Piperacillin/Tazobactam Use in Children with Acute Perforated Appendicitis
title_fullStr 1149. Reducing Piperacillin/Tazobactam Use in Children with Acute Perforated Appendicitis
title_full_unstemmed 1149. Reducing Piperacillin/Tazobactam Use in Children with Acute Perforated Appendicitis
title_short 1149. Reducing Piperacillin/Tazobactam Use in Children with Acute Perforated Appendicitis
title_sort 1149. reducing piperacillin/tazobactam use in children with acute perforated appendicitis
topic Abstracts
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6809157/
http://dx.doi.org/10.1093/ofid/ofz360.1013
work_keys_str_mv AT seddiktalalb 1149reducingpiperacillintazobactamuseinchildrenwithacuteperforatedappendicitis
AT biolaura 1149reducingpiperacillintazobactamuseinchildrenwithacuteperforatedappendicitis
AT bassetthannah 1149reducingpiperacillintazobactamuseinchildrenwithacuteperforatedappendicitis
AT contopoulosioannidisdespina 1149reducingpiperacillintazobactamuseinchildrenwithacuteperforatedappendicitis
AT qureshilubna 1149reducingpiperacillintazobactamuseinchildrenwithacuteperforatedappendicitis
AT schwenkhayden 1149reducingpiperacillintazobactamuseinchildrenwithacuteperforatedappendicitis